Reclast 5mg/100ml IV Infusion Solution Premix from Japan
Reclast is a ready-to-use 5mg zoledronic acid solution in 100ml bottle for once-yearly intravenous infusion in osteoporosis and Paget's disease treatment. Classified under HTS 3004.90.92.75 due to its zoledronic acid content in measured dose retail packing for prophylactic bone therapy. It qualifies as a mixed product (with excipients) for therapeutic uses.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Maintain 2-8°C refrigeration throughout import process with validated temperature logs; include Certificate of Analysis confirming zoledronic acid potency and sterility; watch for EU/US formulation differences triggering additional bioequivalence reviews